CN1270591A - 新的化合物 - Google Patents

新的化合物 Download PDF

Info

Publication number
CN1270591A
CN1270591A CN98809157A CN98809157A CN1270591A CN 1270591 A CN1270591 A CN 1270591A CN 98809157 A CN98809157 A CN 98809157A CN 98809157 A CN98809157 A CN 98809157A CN 1270591 A CN1270591 A CN 1270591A
Authority
CN
China
Prior art keywords
alkyl
compound
phenyl
triazolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98809157A
Other languages
English (en)
Chinese (zh)
Inventor
R·布朗
G·派劳德奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRITISH ASTRA PHARMACEUTICALS Ltd
Original Assignee
BRITISH ASTRA PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRITISH ASTRA PHARMACEUTICALS Ltd filed Critical BRITISH ASTRA PHARMACEUTICALS Ltd
Publication of CN1270591A publication Critical patent/CN1270591A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
CN98809157A 1997-07-22 1998-07-15 新的化合物 Pending CN1270591A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702774-2 1997-07-22
SE9702774A SE9702774D0 (sv) 1997-07-22 1997-07-22 Novel compounds

Publications (1)

Publication Number Publication Date
CN1270591A true CN1270591A (zh) 2000-10-18

Family

ID=20407805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98809157A Pending CN1270591A (zh) 1997-07-22 1998-07-15 新的化合物

Country Status (21)

Country Link
US (1) US6166022A (enExample)
EP (1) EP0998475B1 (enExample)
JP (1) JP2001510843A (enExample)
KR (1) KR20010022084A (enExample)
CN (1) CN1270591A (enExample)
AT (1) ATE216390T1 (enExample)
AU (1) AU8370798A (enExample)
BR (1) BR9811028A (enExample)
CA (1) CA2296426A1 (enExample)
DE (1) DE69804966T2 (enExample)
EE (1) EE200000048A (enExample)
HU (1) HUP0003826A3 (enExample)
ID (1) ID25856A (enExample)
IL (1) IL134111A0 (enExample)
IS (1) IS5352A (enExample)
NO (1) NO20000313L (enExample)
PL (1) PL338181A1 (enExample)
SE (1) SE9702774D0 (enExample)
SK (1) SK188299A3 (enExample)
TR (1) TR200000152T2 (enExample)
WO (1) WO1999005144A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US6369064B1 (en) * 1998-02-17 2002-04-09 Astrazeneca Ab Triazolo(4,5-d)pyrimidine compounds
CA2380656A1 (en) 1999-09-09 2001-03-15 Nadine Derrien Substituted cyclopentenes, their preparation and their use for chiral scaffolds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CN1863789B (zh) 2003-10-03 2010-06-09 博尔托拉制药公司 取代的异喹啉酮
CA2540214A1 (en) 2003-10-03 2005-04-14 Portola Pharmaceuticals, Inc. 2,4-dioxo-3-quinazolinylaryl sulfonylureas
EP1685135B1 (en) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
KR20070064356A (ko) 2004-09-29 2007-06-20 포톨라 파마슈티컬스, 인코포레이티드 치환된 2ｈ-1,3-벤족사진-4(3ｈ)온
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
WO2007056219A2 (en) 2005-11-03 2007-05-18 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
JP2010508350A (ja) 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
WO2011133871A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2576553A4 (en) * 2010-05-27 2013-11-20 Reddys Lab Ltd Dr EXTREMELY SELECTIVE ASYMMETRIC HYDROFORMYLATION OF (+) OR (-) - LACTAM (1S, 4R) - OR (1R, 4S) -2-AZABICYCLO [2.2.1] HEPT-5-EN-3-ONE
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
TR199800019T1 (xx) * 1995-07-11 1998-05-21 Astra Pharmaceuticals Limited Trombosit topaklanmas�n� �nleyici yeni maddeler.

Also Published As

Publication number Publication date
DE69804966T2 (de) 2002-11-07
NO20000313L (no) 2000-03-22
EP0998475B1 (en) 2002-04-17
US6166022A (en) 2000-12-26
CA2296426A1 (en) 1999-02-04
EP0998475A1 (en) 2000-05-10
NO20000313D0 (no) 2000-01-21
ID25856A (id) 2000-11-09
EE200000048A (et) 2000-10-16
HUP0003826A3 (en) 2001-11-28
KR20010022084A (ko) 2001-03-15
JP2001510843A (ja) 2001-08-07
SK188299A3 (en) 2000-08-14
IL134111A0 (en) 2001-04-30
DE69804966D1 (de) 2002-05-23
AU8370798A (en) 1999-02-16
HUP0003826A2 (hu) 2001-04-28
ATE216390T1 (de) 2002-05-15
TR200000152T2 (tr) 2000-07-21
PL338181A1 (en) 2000-10-09
BR9811028A (pt) 2000-08-01
WO1999005144A1 (en) 1999-02-04
IS5352A (is) 2000-01-19
SE9702774D0 (sv) 1997-07-22

Similar Documents

Publication Publication Date Title
CN1270591A (zh) 新的化合物
CN1128801C (zh) 新的三唑并(4,5－d)嘧啶化合物
CN1271359A (zh) 新的化合物
KR100535837B1 (ko) 신규 화합물
JP6323885B2 (ja) ヤヌスキナーゼ（ｊａｋ）阻害剤の硫酸水素塩およびその製造方法
CN103370322B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
CN1432018A (zh) 三唑并[4,5－d]嘧啶化合物的新晶形和非晶形
JP4859321B2 (ja) 新規の［１，２，３］−トリアゾロ［４，５−ｄ］ピリミジン化合物
KR20160146778A (ko) Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
FR2974576A1 (fr) Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
JP2001507023A (ja) トリアゾロ［４，５−ｄ］ピリミジニル誘導体および医薬としてのその使用
WO1999024434A1 (en) Fused pyrazine compounds
JP2001510843A5 (enExample)
JP2025502748A (ja) Ｆｌｔ３の阻害剤としてのピラジン化合物
KR20190035755A (ko) Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
JP6697453B2 (ja) ユビキチン活性化酵素阻害物質及び放射線の投与
JP2003509426A (ja) 新規化合物
JP2002516329A (ja) Ｇ−ｃｓｆ模倣物
JP2002516328A (ja) Ｇ−ｃｓｆ模倣物
JP2003519080A (ja) 新規のトリアゾロ［４，５−ｄ］ピリミジン化合物
TW202102502A (zh) 作為流感病毒複製抑制劑之稠合多環吡啶酮化合物
JP4202752B2 (ja) 新規化合物
CA2821777A1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
JP4190282B2 (ja) 新規化合物
CN1444585A (zh) 晶体治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication